Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price lifted by BMO Capital Markets from $100.00 to $111.00 in a report released on Wednesday morning, Marketbeat Ratings reports. BMO Capital Markets currently has a market perform rating on the stock. Several other equities research analysts have also weighed in on the company. Jefferies Financial […]
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price target increased by JPMorgan Chase & Co. from $133.00 to $134.00 in a research report released on Wednesday, Benzinga reports. They currently have an overweight rating on the stock. Several other equities analysts have also weighed in on the stock. SVB Leerink upgraded shares of Neurocrine […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price objective hoisted by Wedbush from $120.00 to $137.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush’s price target would indicate a potential upside of 18.21% from the company’s current price. Other research […]
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) have received an average rating of “Moderate Buy” from the twenty-one analysts that are covering the company, Marketbeat reports. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The average 12-month target […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the twenty-one analysts that are presently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation and sixteen have assigned a buy recommendation to the company. The average 1 year price objective […]